Stockscreener 앱 받기
266.97
0.35%
-0.95
시간 외 거래:
266.92
-0.05
-0.02%
전일 마감가:
$267.92
열려 있는:
$269.86
하루 거래량:
626.21K
Relative Volume:
0.83
시가총액:
$17.51B
수익:
$1.01B
순이익/손실:
$581.90M
주가수익비율:
30.09
EPS:
8.8733
순현금흐름:
$50.57M
1주 성능:
+0.09%
1개월 성능:
+26.86%
6개월 성능:
+25.17%
1년 성능:
+51.70%
1일 변동 폭
$266.65
$273.80
1주일 범위
$262.18
$274.89
52주 변동 폭
$160.86
$274.89
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
266.97 | 17.57B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S 주식(ASND)의 최신 뉴스
RBC Capital Adjusts Ascendis Pharma Price Target to $280 From $275, Maintains Outperform Rating - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Analysis: Strong Buy Ratings and Promising Revenue Growth Capture Investor Interest - DirectorsTalk Interviews
(ASND) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ASNDAscendis Pharma A/S Volatility & Greeks - Finviz
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data - simplywall.st
Ascendis Pharma Q2 2025 Earnings Preview - MSN
Ascendis Pharma: Behind The Stock Surge - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Ascendis Pharma added to Russell 3000, Russell 1000 and other US indexes - MSN
Ascendis Pharma Unveils Two-Year Pivotal Trial Data for TransCon CNP in Children With Achondroplasia - TipRanks
Ascendis Pharma (ASND) shares 2-year TransCon CNP ApproaCH achondroplasia results - Stock Titan
Ascendis Pharma A/S Announces New Radiographic Data from Week 104 of the Completed Pivotal Approach Trial of Once-Weekly Transcon Cnp in Children with Achondroplasia - marketscreener.com
Ascendis Pharma reports new radiographic data from Week 104 from ApproaCH Trial - TipRanks
Ascendis Pharma A/SAnnounces Week 104 Data From Approach Trial Of Transcon CNP In Children With Achondroplasia - TradingView
Ascendis drug data show leg alignment kept improving through 2 years - Stock Titan
Children with Achondroplasia Treated with TransCon CNP - GlobeNewswire
Big Pharma Has a Case of Merger Mania - The Motley Fool
Ascendis Pharma A/S(NasdaqGS:ASND) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital - TipRanks
Ascendis Pharma (ASND) adds 177,267 shares via warrant exercises - Stock Titan
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 2500 Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell Midcap Value Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell Midcap Growth Benchmark - marketscreener.com
Sit Mid Cap Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $288 - 富途牛牛
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000E Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 1000 Value Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 1000 Growth Benchmark - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000E Index - marketscreener.com
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000E Value Benchmark - marketscreener.com
Ascendis Pharma (ASND) moves 9.9% higher: Will this strength last? - MSN
Ascendis Pharma A/S(NasdaqGS: ASND) added to Russell 3000 Value Benchmark - marketscreener.com
Ascendis Pharma added to Russell 1000 and other indexes By Investing.com - Investing.com Australia
Ascendis Pharma joins multiple Russell U.S. indexes, boosting its market visibility. - Pluang
Ascendis Pharma added to Russell 1000 and other indexes - Investing.com UK
Ascendis Pharma (ASND) Joins Russell Indexes in 2026 Reconstitution - GuruFocus
Ascendis Pharma (ASND) Joins Multiple Russell Indexes - GuruFocus
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap - marketscreener.com
Ascendis Joins Multiple Russell U.S. Indexes, Including the - GlobeNewswire
What Does YUVIWEL's FDA Approval Mean for Ascendis Pharma - Kavout | AI
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last? - Yahoo Finance
Ascendis Pharma reveals positive trial data for achondroplasia treatments at ICCBH 2026. - Pluang
Ascendis to show 104-week achondroplasia data in Montreal - Stock Titan
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - GlobeNewswire
Ascendis Pharma jumps as investors weigh cash boost, pipeline momentum, and possible index-related buying - Quiver Quantitative
Ascendis Pharma (ASND) Could Be 30% Undervalued Following Mixed Share Price Moves - simplywall.st
(ASND) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Final Trades: Ascendis Pharma, Monolithic Power, The IYC And The GPIQ Corinthians X São Paulo (waHz3aMVr9) - Mshale
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating - 富途牛牛
Ascendis Pharma A/S (ASND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ascendis Pharma A/S (ASND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ascendis Pharma A S (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ascendis Pharma A S 주식 (ASND) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
1.18%
2.48%
자본화:
|
볼륨(24시간):